Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
AT9283 is a novel, potent multikinase inhibitor with potential antineoplastic activity and has the potential for the treatment of multiple myeloma. It inhibits JAK2/3 with IC50 of 1.2 nM/1.1 nM in cell-free assays. AT9283 binds to and inhibits Aurora kinases A and B, JAK2 and the kinase BCR-ABL, which may result in the inhibition of cellular division and proliferation and the induction of apoptosis in tumor cells that overexpress these kinases.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
J Med Chem.2009 Jan 22;52(2):379-88.
|
Molecular Formula |
C19H24CLN7O2
|
|
---|---|---|
Molecular Weight |
417.89
|
|
Exact Mass |
417.167
|
|
CAS # |
896466-61-8
|
|
Related CAS # |
896466-61-8 (HCl);896466-04-9;896466-76-5 (lactate);
|
|
PubChem CID |
135461257
|
|
Appearance |
Typically exists as solid at room temperature
|
|
Hydrogen Bond Donor Count |
5
|
|
Hydrogen Bond Acceptor Count |
5
|
|
Rotatable Bond Count |
5
|
|
Heavy Atom Count |
29
|
|
Complexity |
554
|
|
Defined Atom Stereocenter Count |
0
|
|
SMILES |
O=C(NC1CC1)NC2=CNN=C2C=3NC4=C(N3)C=C(C=C4)CN5CCOCC5.Cl
|
|
InChi Key |
NHFNYIVVGIXBPD-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C19H23N7O2.ClH/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26;/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27);1H
|
|
Chemical Name |
1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3930 mL | 11.9649 mL | 23.9297 mL | |
5 mM | 0.4786 mL | 2.3930 mL | 4.7859 mL | |
10 mM | 0.2393 mL | 1.1965 mL | 2.3930 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Abstract Image Figure 4 |
AT9283 potently inhibits Aurora B activity in B-NHL cell lines.Int J Cancer.2012 Jun 15;130(12):2997-3005. td> |
Figure 5 AT9283 plus docetaxel suppresses tumor growth and prolong survival of Granta-519-SCID xenografted mice.Int J Cancer.2012 Jun 15;130(12):2997-3005. td> |